Biofil Chemicals and Pharmaceuticals Limited (BOM:524396)
India
· Delayed Price · Currency is INR 30.31
-1.19 (-3.78%)
At close: Mar 9, 2026
BOM:524396 Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2020 - 2016 |
| Operating Revenue | 291.81 | 334.02 | 400.35 | 300.35 | 223.82 | 357.5 | Upgrade
|
| Other Revenue | 30.85 | 1.8 | 3.73 | - | - | 0.59 | Upgrade
|
| Revenue | 322.66 | 335.82 | 404.09 | 300.35 | 223.82 | 358.1 | Upgrade
|
| Revenue Growth (YoY) | -20.55% | -16.89% | 34.54% | 34.19% | -37.50% | 20.30% | Upgrade
|
| Cost of Revenue | 271.58 | 310.16 | 376.61 | 274.72 | 195.16 | 324.83 | Upgrade
|
| Gross Profit | 51.08 | 25.67 | 27.48 | 25.63 | 28.66 | 33.27 | Upgrade
|
| Selling, General & Admin | 9.58 | 7.97 | 6.82 | 6.34 | 7.94 | 7.59 | Upgrade
|
| Other Operating Expenses | 6.62 | 6.62 | 7.66 | 6.66 | 6.1 | 1.94 | Upgrade
|
| Operating Expenses | 19.01 | 18.38 | 18.47 | 17.29 | 18.32 | 13.64 | Upgrade
|
| Operating Income | 32.08 | 7.29 | 9 | 8.34 | 10.34 | 19.63 | Upgrade
|
| Interest Expense | -0.17 | -0.36 | -0.4 | -0.42 | -0.39 | -0.64 | Upgrade
|
| Interest & Investment Income | 0.44 | 0.44 | 0.07 | 0.02 | 0.21 | 0.21 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.01 | -0.01 | -0.02 | -0.01 | -0.02 | -0.04 | Upgrade
|
| EBT Excluding Unusual Items | 32.34 | 7.36 | 8.65 | 7.93 | 10.15 | 19.16 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | - | - | 0.03 | Upgrade
|
| Pretax Income | 32.34 | 7.36 | 8.65 | 7.93 | 10.15 | 19.19 | Upgrade
|
| Income Tax Expense | 4.61 | 1.78 | 1.56 | 2.33 | 3.17 | 6.78 | Upgrade
|
| Net Income | 27.73 | 5.58 | 7.09 | 5.6 | 6.98 | 12.41 | Upgrade
|
| Net Income to Common | 27.73 | 5.58 | 7.09 | 5.6 | 6.98 | 12.41 | Upgrade
|
| Net Income Growth | 357.04% | -21.36% | 26.55% | -19.76% | -43.74% | 2.83% | Upgrade
|
| Shares Outstanding (Basic) | 16 | 16 | 16 | 16 | 16 | 16 | Upgrade
|
| Shares Outstanding (Diluted) | 16 | 16 | 16 | 16 | 16 | 16 | Upgrade
|
| Shares Change (YoY) | 0.84% | - | - | - | - | -0.00% | Upgrade
|
| EPS (Basic) | 1.70 | 0.34 | 0.44 | 0.34 | 0.43 | 0.76 | Upgrade
|
| EPS (Diluted) | 1.70 | 0.34 | 0.44 | 0.34 | 0.43 | 0.76 | Upgrade
|
| EPS Growth | 352.51% | -21.98% | 28.17% | -20.77% | -43.74% | 3.08% | Upgrade
|
| Free Cash Flow | - | -20.24 | 23.71 | -1.22 | -2.9 | 5.44 | Upgrade
|
| Free Cash Flow Per Share | - | -1.24 | 1.46 | -0.07 | -0.18 | 0.33 | Upgrade
|
| Gross Margin | 15.83% | 7.64% | 6.80% | 8.53% | 12.80% | 9.29% | Upgrade
|
| Operating Margin | 9.94% | 2.17% | 2.23% | 2.78% | 4.62% | 5.48% | Upgrade
|
| Profit Margin | 8.60% | 1.66% | 1.75% | 1.87% | 3.12% | 3.47% | Upgrade
|
| Free Cash Flow Margin | - | -6.03% | 5.87% | -0.41% | -1.29% | 1.52% | Upgrade
|
| EBITDA | 35.72 | 11.08 | 13 | 12.63 | 14.62 | 23.75 | Upgrade
|
| EBITDA Margin | 11.07% | 3.30% | 3.22% | 4.21% | 6.53% | 6.63% | Upgrade
|
| D&A For EBITDA | 3.65 | 3.8 | 3.99 | 4.29 | 4.28 | 4.12 | Upgrade
|
| EBIT | 32.08 | 7.29 | 9 | 8.34 | 10.34 | 19.63 | Upgrade
|
| EBIT Margin | 9.94% | 2.17% | 2.23% | 2.78% | 4.62% | 5.48% | Upgrade
|
| Effective Tax Rate | 14.26% | 24.23% | 18.04% | 29.33% | 31.19% | 35.31% | Upgrade
|
| Revenue as Reported | 323.91 | 337.07 | 405.25 | 301.32 | 225.33 | 365.5 | Upgrade
|
| Advertising Expenses | - | 0.12 | 0.12 | 0.1 | 0.07 | 0.07 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.